Regulatory Press Releases
CORRECTION: Clarification and extended information on previous press release regarding convertible loans and their structure.
Malmö, 24 August 2023 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA), ("Pila Pharma" or the "Company") announces a correction regarding the press release "PILA PHARMA announces capital infusion via convertible loans" which was published earlier today, 24 August 2023. The correction refers to the fact that the press release lacked significant information on…
PILA PHARMA announces capital infusion via convertible loans
Malmö, 24 August 2023 Download the press release as PDF here The board of Pila Pharma AB (publ) has decided to immediately secure additional funds via convertible loan agreements to sponsor the next clinical trial applications. With the recent news that our tablets manufactured in 2021 are cleared by the manufacturer for use in phase 1 or 2a studies, Pila…
PILA PHARMA publishes interim report (1 April – 30 June 2023)
Malmö, 23 August, 2023 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s interim report for the period April – June 2023. The report can be found on the Company´s website:https://pilapharma.com/investors/finansiell-information/ SUMMARY OF INTERIM REPORT Second quarter (1 April- 30 June 2023) Operating income amounted to TSEK 301 (651) The operating result…
Pila Pharma AB publishes interim report (1 January – 31 March 2023)
Malmö, April 26, 2023 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s interim report for the period January – March 2023 and it is now available on the Company´s homepage, https://pilapharma.com/investors/finansiell-information/, and as an attachment to this press release. SUMMARY OF INTERIM REPORT First quarter (1 January - 31 March 2023)…
Pila Pharma AB publicerar publicerar delårsrapport (1 januari – 31 mars 2023)
Malmö, 26 april 2023 Läs pressmeddelandet som PDF här Pila Pharma AB (publ) (FN STO: PILA) publicerar i dag bolagets delårsrapport för perioden januari – mars 2023 som finns tillgänglig på bolagets hemsida: https://pilapharma.com/investors/finansiell-information/, samt som bilaga till detta pressmeddelande. SAMMANFATTNING AV DELÅRSRAPPORT Första kvartalet (1 januari - 31 mars 2023) Rörelsens intäkter uppgick till 796 kSEK (535) Rörelseresultatet (EBIT) uppgick…